title: Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
authors: Diego
authors: D
authors: Conde
authors: Juan Pablo
authors: JP
authors: Costabel
authors: Martin
authors: M
authors: Aragon
authors: Milagros
authors: M
authors: Caro
authors: Alejandra
authors: A
authors: Ferro
authors: Andres
authors: A
authors: Klein
authors: Marcelo
authors: M
authors: Trivi
authors: Alberto
authors: A
authors: Giniger
mesh_terms: D000840:Anisoles / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D004562:Electrocardiography; D005060:Europe; D005424:Flecainide / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D011405:Propafenone / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*
chemical_list: D000840:Anisoles; D000889:Anti-Arrhythmia Agents; D011759:Pyrrolidines; D011405:Propafenone; C524581:vernakalant; D005424:Flecainide